



RECEIVED

JUN 29 2001


1614

TECH CENTER 1600/2900

Patent Docket P1805R1

THE UNITED STATES PATENT AND TRADEMARK OFFICE

P117

In re Application of  Avi J. Ashkenazi et al.  Serial No.: 09/724,341  Filed: November 28, 2000  For: <b>USES OF AGONISTS AND ANTAGONISTS TO MODULATE ACTIVITY OF TNF-RELATED MOLECULES</b>	Group Art Unit: 1614  Examiner:    <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  June 20, 2001   Eileen Ly
---	--

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith a copy of the PCT search report issued in Applicants counterpart PCT application, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. All of the references cited in the search report have previously been cited in Applicants Form 1449.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

#92308

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By:

*Diane L. Marschang*

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE